Business Context and Reporting Period
This Form 8-K Current Report was filed by Dyne Therapeutics, Inc. on June 22, 2026. The report discloses corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the appointment of a director and associated compensation arrangements.
Material Changes
The primary material change reported is the election of Barry E. Greene as a Class I director on June 22, 2026. Mr. Greene serves until the 2027 Annual Meeting of Stockholders or until his successor is elected. The Board has determined Mr. Greene is an "independent" director under Nasdaq rules.
Guidance, Outlook, and Compensation Details
There is no forward-looking guidance, outlook, or discussion of risks and contingencies in this filing. The report details the following compensatory arrangements for the new director:
- Equity Grant: An option to purchase 57,463 shares of common stock at an exercise price of $20.87 per share (the closing price on the grant date).
- Vesting Schedule: Options vest in equal monthly installments over three years, subject to continued service. Full acceleration occurs in the event of a change in control.
- Cash Compensation: Annual cash compensation of $45,000 as a Board member.
- Other Benefits: Annual equity grants per the non-employee director program and reimbursement for reasonable travel and out-of-pocket expenses.
Investor Verification Checklist
- Verify the independence status of Barry E. Greene under Nasdaq rules.
- Confirm the total number of outstanding options granted under the 2020 Stock Incentive Plan.
- Review the Company's standard form of indemnification agreement (referenced as Exhibit 10.10 to the 2020 Form S-1).
- Monitor future filings for the impact of the new director on Board committee assignments.